Published in J Urol on September 07, 2013
Can Confirmatory Biopsy be Omitted in Patients with Prostate Cancer Favorable Diagnostic Features on Active Surveillance? J Urol (2015) 2.04
The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol (2015) 1.25
Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int (2015) 0.86
Applying precision medicine to the active surveillance of prostate cancer. Cancer (2015) 0.85
The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol (2014) 0.83
Prostate cancer detection rate in patients with fluctuating prostate-specific antigen levels on the repeat prostate biopsy. Prostate Int (2014) 0.82
Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation. Prostate Cancer Prostatic Dis (2015) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Risk factors for infection following prostate biopsy - a case control study. BMC Infect Dis (2015) 0.80
Infections after fiducial marker implantation for prostate radiotherapy: are we underestimating the risks? Radiat Oncol (2015) 0.80
Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance. BJU Int (2015) 0.79
A single dose of meropenem is superior to ciprofloxacin in preventing infections after transrectal ultrasound-guided prostate biopsies in the era of quinolone resistance. World J Urol (2016) 0.78
Optimizing safety and accuracy of prostate biopsy. Curr Opin Urol (2016) 0.77
Reducing Infectious Complications Following Transrectal Ultrasound-guided Prostate Biopsy: A Systematic Review. Rev Urol (2016) 0.77
High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance. PLoS One (2015) 0.77
Comparative Effectiveness of Single versus Combination Antibiotic Prophylaxis for Infections after Transrectal Prostate Biopsy. Antimicrob Agents Chemother (2015) 0.76
Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis. BMC Health Serv Res (2016) 0.75
Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer. Am J Prev Med (2015) 0.75
Increase of prostate biopsy-related bacteremic complications in southern Finland, 2005-2013: a population-based analysis. Prostate Cancer Prostatic Dis (2016) 0.75
Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols. BJU Int (2015) 0.75
Transrectal-ultrasound prostatic biopsy preparation: rectal enema vs. mechanical bowel preparation. Cent European J Urol (2015) 0.75
MR-targeted TRUS prostate biopsy using local reference augmentation: initial experience. Int Urol Nephrol (2016) 0.75
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy? Can Urol Assoc J (2017) 0.75